Abstract
Microalbuminuria has been used to detect subjects at risk of cardiovascular disease and chronic kidney disease (CKD) in patients with diabetes, those with hypertension, and the general population. However, relatives of patients with CKD have not been investigated for microalbuminuria in the United Kingdom. A cross-sectional study evaluating the prevalence of microalbuminuria in relatives of patients with CKD compared with the general population of Sheffield, England. Participants in the Kidney Evaluation and Awareness Program in Sheffield, a population-based screening program for microalbuminuria. 274 relatives of patients with CKD were studied and compared with an age- and sex-matched control group from the general population. Family history of CKD. Screening tools included a questionnaire collating information for demographics, lifestyle, and medical and family history of diabetes, hypertension, and CKD. Urine samples were collected for microalbuminuria estimation. Microalbuminuria measurements were obtained by using immunonephelometry. Microalbuminuria thresholds were defined using albumin-creatinine ratio. The prevalence of microalbuminuria was 9.5% in those with a family history of CKD. This was significantly greater than the prevalence of 1.4% in the age- and sex-matched control group with no family history of CKD (P = 0.001). Independent determinants of microalbuminuria in the study population in an adjusted logistic regression model were family history of diabetes (odds ratio [OR], 2.88; 95% confidence interval, 1.17 to 7.04), obesity (OR, 3.29; 95% confidence interval, 1.61 to 6.69), and family history of CKD (OR, 6.96; 95% confidence interval, 3.48 to 13.92). Cross-sectional snapshot analysis, microalbuminuria measured once. The prevalence of microalbuminuria in relatives of patients with CKD is greater than in an age- and sex-matched control group from the general population. The prognostic value of microalbuminuria in this category of at-risk population remains to be determined in longitudinal studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.